(NASDAQ: AMRX) Amneal Pharmaceuticals's forecast annual revenue growth rate of 6.77% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 3.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.87%.
Amneal Pharmaceuticals's revenue in 2025 is $2,830,186,000.On average, 3 Wall Street analysts forecast AMRX's revenue for 2025 to be $942,992,756,162, with the lowest AMRX revenue forecast at $940,916,978,158, and the highest AMRX revenue forecast at $945,643,345,711. On average, 3 Wall Street analysts forecast AMRX's revenue for 2026 to be $1,012,289,829,501, with the lowest AMRX revenue forecast at $982,100,313,467, and the highest AMRX revenue forecast at $1,033,432,175,391.
In 2027, AMRX is forecast to generate $1,077,969,100,409 in revenue, with the lowest revenue forecast at $1,030,147,537,993 and the highest revenue forecast at $1,125,790,662,824.